USPTO Patent Granted For HemaXis Microfluidic Blood Collection Platform
We are proud to announce the USPTO patent covering our 1st Generation…
DBS System raises CHF 2.5M to produce revolutionary micro blood collection device capable of true passive plasma separation
DBS System announced it closed its Series A at CHF 2.5M which…
DBS System recognized as a Top 50 Startup by Bilan
The DBS System team is proud to announce that Bilan selected…
Nest investira une part de son capital dans des start-up
La fondation collective entame un partenariat inédit avec la…
MEDICA 2016 Düsseldorf, Germany, Hall 3 / K45 - Nov 14 - 16, 2016
Visit us in the booth of MiniFab, our development and manufacturing…
RTS Radio Interview with Dr. Julien Déglon
RTS Interview with our Co-Founder & CTO Dr. Julien D…
Tech Tour announces the top 20 Medtech companies in Europe
Geneva and Brussels, June 30th, 2015 - The Tech Tour today announced…
300’000 CHF pour le développement de DBS System
10364 Comments
/
DBS System a obtenu un prêt Early de 300’000 CHF de la Fondation…
DISCLAIMER
HemaXis DB is a FDA Class 1 medical device. HemaXis DX is in development and for research purposes only. Use of HemaXis devices in Laboratory Developed Tests (LDTs) requires further processing including the establishment of performance characteristics and successful validation by the laboratory in a manner consistent with local regulatory requirements.
By using this website you are agreeing to our Terms and Conditions.
CONTACT
DBS System SA
Rte des Avouillons 4
CH-1196 Gland
Switzerland
Tel: +41 (0) 78 624 70 15
Email: info@dbs-system.ch